Several studies have demonstrated a significant decrease in uric acid levels in patients treated with SGLT-2 inhibitors, which may have important clinical implications as hyperuricemia is associated with an increased risk of cardiovascular and renal disease [51]. This evidence concerns the gene SLC5A2 and kidney disorder.